Published in Blood on September 16, 2008
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol (2010) 1.67
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr (2009) 1.61
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood (2015) 1.58
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int (2010) 1.56
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J Hum Genet (2012) 1.46
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood (2014) 1.42
Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol (2011) 1.38
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol (2012) 1.30
Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2011) 1.29
Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol (2010) 1.28
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 1.28
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J (2009) 1.13
Hemolytic uremic syndrome. Semin Immunopathol (2014) 1.12
Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) (2012) 1.10
Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta (2010) 1.08
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol (2011) 1.06
Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol (2014) 1.04
Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine. Kidney Int (2013) 1.04
Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol (2010) 1.03
The complotype: dictating risk for inflammation and infection. Trends Immunol (2012) 1.03
Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Curr Opin Immunol (2015) 1.03
EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5. Infect Immun (2010) 1.02
Thrombotic microangiopathies. ISRN Hematol (2012) 0.99
Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One (2013) 0.98
Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol (2012) 0.97
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol (2015) 0.96
New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep (2014) 0.96
Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2014) 0.94
Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol (2011) 0.92
Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol (2010) 0.89
Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options. Pediatr Nephrol (2009) 0.88
Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PLoS One (2014) 0.87
The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol (2015) 0.87
Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther (2012) 0.86
Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol (2014) 0.86
Early treatment with eculizumab in atypical haemolytic uraemic syndrome. Clin Kidney J (2012) 0.85
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol (2012) 0.84
A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus (2009) 0.84
Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr (2013) 0.83
Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited. Clin Immunol (2012) 0.83
The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol (2014) 0.83
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) (2010) 0.82
Management of hemolytic uremic syndrome. F1000Prime Rep (2014) 0.82
Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol (2011) 0.81
Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol (2015) 0.80
Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Arch (2013) 0.80
Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol (2014) 0.80
Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack. J Immunol (2013) 0.80
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep (2015) 0.79
Hemolytic uremic syndrome. Turk Pediatri Ars (2015) 0.79
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J (2016) 0.79
Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol (2015) 0.79
Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res (2014) 0.79
The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost (2016) 0.78
Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. J Clin Immunol (2016) 0.77
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) (2014) 0.77
The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet (2016) 0.77
Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2014) 0.77
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol (2015) 0.76
Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol (2016) 0.76
A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol (2015) 0.76
Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol (2013) 0.76
Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant (2016) 0.76
Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. J Immunol (2015) 0.76
A novel mutation in the complement component 3 gene in a patient with selective IgA deficiency. J Clin Immunol (2012) 0.75
The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol (2016) 0.75
Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern. Case Rep Nephrol (2016) 0.75
Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology (2016) 0.75
Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. Sci Rep (2016) 0.75
Complement related kidney diseases: Recurrence after transplantation. World J Transplant (2016) 0.75
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Structures of complement component C3 provide insights into the function and evolution of immunity. Nature (2005) 4.01
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Structure of C3b reveals conformational changes that underlie complement activity. Nature (2006) 3.22
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet (2001) 2.75
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 2.23
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med (2006) 1.97
Atypical haemolytic uraemic syndrome. Br Med Bull (2006) 1.85
Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). J Biol Chem (2000) 1.84
Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with alpha 2-macroglobulin. Biochem J (1981) 1.78
Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol (2006) 1.70
Structural insights into the central complement component C3. Mol Immunol (2006) 1.25
Molecular basis of hereditary C3 deficiency. J Clin Invest (1990) 1.20
Mutagenesis of the Arg-Gly-Asp triplet in human complement component C3 does not abolish binding of iC3b to the leukocyte integrin complement receptor type III (CR3, CD11b/CD18). J Biol Chem (1992) 1.03
Genomic organization of human complement component C3. Genomics (1990) 1.00
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet (2003) 5.24
The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. Nat Genet (2007) 4.63
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis (2005) 3.28
Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Pediatr Nephrol (2011) 3.26
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet (2002) 2.64
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Assisted peritoneal dialysis. Experience in a French renal department. Perit Dial Int (2006) 2.53
Adenovirus type 11 uses CD46 as a cellular receptor. J Virol (2003) 2.52
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol (2008) 2.30
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Controversies in the management of vesicoureteral reflux: the rationale for the RIVUR study. J Pediatr Urol (2009) 2.26
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 2.23
Complement driven by conformational changes. Nat Rev Immunol (2008) 2.21
Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr (2006) 2.15
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Idiopathic mid-aortic syndrome in children. Pediatr Nephrol (2008) 2.14
Insight into organometallic intermediate and its evolution to covalent bonding in surface-confined ullmann polymerization. ACS Nano (2013) 2.11
Death after withdrawal from dialysis: the most common cause of death in a French dialysis population. Nephrol Dial Transplant (2004) 2.10
Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol (2010) 2.08
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J Am Soc Nephrol (2007) 2.06
Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. Ann Intern Med (2010) 2.05
Allowing patients to choose the ethnicity of attending doctors is institutional racism. BMJ (2014) 2.04
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int (2009) 2.01
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 1.98
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med (2006) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol (2008) 1.94
Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet (2008) 1.93
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci (2009) 1.86
Atypical haemolytic uraemic syndrome. Br Med Bull (2006) 1.85
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant (2005) 1.82
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol (2006) 1.81
Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol (2005) 1.80
Controlled formation of sharp zigzag and armchair edges in graphitic nanoribbons. Science (2009) 1.77
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Randomized sham-controlled trial to evaluate the safety and effectiveness of a high-intensity focused ultrasound device for noninvasive body sculpting. Plast Reconstr Surg (2011) 1.75
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Membrane targeting and secretion of mutant uromodulin in familial juvenile hyperuricemic nephropathy. J Am Soc Nephrol (2006) 1.73
Vaccination of chickens against H5N1 avian influenza in the face of an outbreak interrupts virus transmission. Avian Pathol (2004) 1.72
Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis (2004) 1.71
Medication errors in hospitals: computerized unit dose drug dispensing system versus ward stock distribution system. Pharm World Sci (2003) 1.70
Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol (2008) 1.68